G proteins, p60TRP, and neurodegenerative diseases

Molecular Neurobiology

Volumn 47, Issue 3, 2013, Pages 1103-1111

  Heese, Klaus ^a  

^a Hanyang University   (South Korea)

Author keywords

ALS; Alzheimer's disease; APP; BHLHB9; CpG island hypermethylation; G protein; GASP; GPCR; GPRASP; Huntington's disease; P60TRP; Parkinson's disease; PIPS; Schizophrenia; Tau

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; G PROTEIN COUPLED RECEPTOR; GAMMA SECRETASE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; OREXIN; PROTEIN P60; RAB PROTEIN; REGULATOR PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR;

ARTICLE; CATALYSIS; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DNA METHYLATION; ENDOCYTOSIS; NERVE CELL PLASTICITY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; ENDOCYTOSIS; EPIGENESIS, GENETIC; GTP-BINDING PROTEINS; HUMANS; NEURODEGENERATIVE DISEASES; NEURONAL PLASTICITY;

EID: 84887293644     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8410-1     Document Type: Article

References (95)

1. Maurer K, Volk S, Gerbaldo H. (1997) Auguste D and Alzheimer's disease. Lancet 349:1546-1549
2. Alzheimer A, Stelzmann RA, Schnitzlein H.N., Murtagh F.R. (1995) An English translation of Alzheimer's 1907 paper, "Über eine eigenartige Erkankung der Hirnrinde,". Clin Anat 8:429-431
3. Heese K, Akatsu H. (2006) Alzheimer's disease-an interactive perspective. Curr Alzheimer Res 3:109-121
4. Graeber MB, Kosel S, Egensperger R., Banati RB, Muller U, Bise K, Hoff P., Moller HJ, Fujisawa K, Mehraein P (1997) Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. Neurogenetics 1:73-80
5. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430:631-639
6. Selkoe DJ, Schenk D. (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545-584
7. Goedert M, Klug A, Crowther R.A. (2006) Tau protein, the paired helical filament and Alzheimer's disease. J Alzheimers Dis 9:195-207
8. Hardy J, Selkoe D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356
9. Palop JJ, Mucke L. (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 13:812-818
10. Lee VM (2001) Biomedicine. Tauists and beta-aptists united-well almost! Science 293:1446-1447
11. Heese K, Yamada T, Akatsu H., Yamamoto T, Kosaka K, Nagai Y., Sawada T. (2004) Characterizing the new transcription regulator protein p60TRP J Cell Biochem 91:1030-1042
12. Neves SR, Ram PT, Iyengar R. (2002) G protein pathways. Science 296:1636-1639
13. Cabrera-Vera T.M., Vanhauwe J, Thomas T.O., Medkova M., Preininger A, Mazzoni MR, Hamm H.E. (2003) Insights into G protein structure, function, and regulation. Endocr Rev 24:765-781
14. Nishimoto I, Okamoto T, Matsuura Y., Takahashi S, Murayama Y, Ogata E. (1993) Alzheimer amyloid protein precursor complexes with brain GTP-binding protein G(o). Nature 362:75-79
15. Ikezu T, Okamoto T, Komatsuzaki K., Matsui T, Martyn JA, Nishimoto I. (1996) Negative transactivation of cAMP response element by familial Alzheimer's mutants of APP. EMBO J 15:2468-2475
16. Yamatsuji T, Matsui T, Okamoto T., Komatsuzaki K, Takeda S, Fukumoto H., Iwatsubo T, Suzuki N, Asami-Odaka A, Ireland S, Kinane TB, Giambarella U, Nishimoto I (1996) G proteinmediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP. Science 272:1349-1352
17. Giambarella U, Murayama Y, Ikezu T., Fujita T, Nishimoto I. (1997) Potential CRE suppression by familial Alzheimer's mutants of APP independent of adenylyl cyclase regulation. FEBS Lett 412:97-101
18. Giambarella U, Yamatsuji T, Okamoto T., Matsui T, Ikezu T, Murayama Y., Levine MA, Katz A, Gautam N, Nishimoto I (1997) G protein betagamma complex-mediated apoptosis by familial Alzheimer's disease mutant of APP. EMBO J 16:4897-4907
19. Nishimoto I (1998) A new paradigm for neurotoxicity by FAD mutants of betaAPP: a signaling abnormality. Neurobiol Aging 19: S33-S38
20. Shaked GM, Chauv S, Ubhi K., Hansen LA, Masliah E. (2009) Interactions between the amyloid precursor protein C-terminal domain and G proteins mediate calcium dysregulation and amyloid beta toxicity in Alzheimer's disease. FEBS J 276:2736-2751
21. Thathiah A, De Strooper B (2009) G protein-coupled receptors, cholinergic dysfunction, and Abeta toxicity in Alzheimer's disease. Sci Signal 2:re8
22. Bakshi P, Jin C, Broutin P., Berhane B, Reed J, Mullan M. (2009) Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta. Bioorg Med Chem 17:8102-8112
23. Teng L, Zhao J, Wang F., Ma L, Pei G. (2010) A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis. Cell Res 20:138-153
24. Thathiah A, De Strooper B (2011) The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat Rev Neurosci 12:73-87
25. Jiang Y, Mullaney KA, Peterhoff C.M., Che S., Schmidt SD, Boyer-Boiteau A, Ginsberg SD, Cataldo A.M., Mathews PM, Nixon RA (2010) Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci USA 107:1630-1635
26. Ginsberg SD, Mufson EJ, Counts S.E., Wuu J., Alldred MJ, Nixon RA, Che S. (2010) Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 22:631-639
27. Li G (2011) Rab GTPases, membrane trafficking and diseases. Curr Drug Targets 12:1188-1193
28. Kimura N, Inoue M, Okabayashi S., Ono F, Negishi T. (2009) Dynein dysfunction induces endocytic pathology accompanied by an increase in Rab GTPases: a potential mechanism underlying age-dependent endocytic dysfunction. J Biol Chem 284:31291-31302
29. Kimura N, Okabayashi S, Ono F. (2012) Dynein dysfunction disrupts intracellular vesicle trafficking bidirectionally and perturbs synaptic vesicle docking via endocytic disturbances a potential mechanism underlying age-dependent impairment of cognitive function. Am J Pathol 180:550-561
30. Mieda M, Sakurai T. (2009) Integrative physiology of orexins and orexin receptors. CNS Neurol Disord Drug Targets 8:281-295
31. Kodadek T, Cai D. (2010) Chemistry and biology of orexin signaling. Mol Biosyst 6:1366-1375
32. Matsuki T, Sakurai T. (2008) Orexins and orexin receptors: from molecules to integrative physiology. Results Probl Cell Differ 46:27-55
33. Sakurai T, Mieda M, Tsujino N. (2010) The orexin system: roles in sleep/wake regulation. Ann N Y Acad Sci 1200:149-161
34. Gatfield J, Brisbare-Roch C, Jenck F., Boss C. (2010) Orexin receptor antagonists: a new concept in CNS disorders? ChemMedChem 5:1197-1214
35. Winrow CJ, Tanis KQ, Reiss D.R., Rigby AM, Uslaner JM, Uebele VN, Doran S.M., Fox SV, Garson SL, Gotter AL, Levine DM, Roecker AJ, Coleman PJ, Koblan KS, Renger JJ (2010) Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology 58:185-194
36. Coleman PJ, Renger J.J. (2010) Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opin Ther Pat 20:307-324
37. Roos RA, Aziz N.A. (2007) Hypocretin-1 and secondary signs in Huntington's disease. Parkinsonism Relat Disord 13:S387-S390
38. Aziz A, Fronczek R, Maat-Schieman M, Unmehopa U., Roelandse F, Overeem S, van Duinen S, Lammers GJ, Swaab D, Roos R (2008) Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol 18:474-483
39. Baumann CR, Hersberger M, Bassetti C.L. (2006) Hypocretin-1 (orexin A) levels are normal in Huntington's disease. J Neurol 253:1232-1233
40. Meier A, Mollenhauer B, Cohrs S., Rodenbeck A, Jordan W, Meller J., Otto M. (2005) Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease. Brain Res 1063:201-203
41. Thannickal TC, Lai YY, Siegel J.M. (2007) Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130:1586-1595
42. Fronczek R, Overeem S, Lee S.Y., Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF (2007) Hypocretin (orexin) loss in Parkinson's disease. Brain 130:1577-1585
43. Yasui K, Inoue Y, Kanbayashi T., Nomura T, Kusumi M, Nakashima K. (2006) CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 250:120-123
44. Kang JE, Lim MM, Bateman R.J., Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S., Holtzman D.M. (2009) Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326:1005-1007
45. Abu-Helo A., Simonin F. (2010) Identification and biological significance of G protein-coupled receptor associated sorting proteins (GASPs). Pharmacol Ther 126:244-250
46. Moser E, Kargl J, Whistler J.L., Waldhoer M., Tschische P. (2010) G protein-coupled receptor-associated sorting protein 1 regulates the postendocytic sorting of seven-transmembrane-spanning g proteincoupled receptors. Pharmacology 86:22-29
47. Mishra M, Heese K. (2011) P60TRP interferes with the GPCR/secretase pathway to mediate neuronal survival and synaptogene-sis. J Cell Mol Med 15:2462-2477
48. Matsuki T, Kiyama A, Kawabuchi M., Okada M, Nagai K. (2001) A novel protein interacts with a clock-related protein, rPer1. Brain Res 916:1-10
49. Kiyama A, Isojima Y, Nagai K. (2006) Role of Per1-interacting protein of the suprachiasmatic nucleus in NGF mediated neuronal survival. Biochem Biophys Res Commun 339:514-519
50. Santagata S, Boggon TJ, Baird C.L., Gomez CA, Zhao J, Shan WS, Myszka D.G., Shapiro L. (2001) G-protein signaling through tubby proteins. Science 292:2041-2050
51. White JH, McIllhinney RA, Wise A, Ciruela F., Chan WY, Emson PC, Billinton A, Marshall F.H. (2000) The GABAB receptor interacts directly with the related transcription factors CREB2 and ATFx. Proc Natl Acad Sci USA 97:13967-13972
52. Nagoshi E, Yoneda Y. (2001) Dimerization of sterol regulatory element-binding protein 2 via the helix-loop-helix-leucine zipper domain is a prerequisite for its nuclear localization mediated by importin beta. Mol Cell Biol 21:2779-2789
53. Zinser EG, Hartmann T, Grimm M.O. (2007) Amyloid beta-protein and lipid metabolism. Biochim Biophys Acta 1768:1991-2001
54. Uyeda K, Yamashita H, Kawaguchi T. (2002) Carbohydrate responsive element-binding protein (ChREBP): a key regulator of glucose metabolism and fat storage. Biochem Pharmacol 63:2075-2080
55. Dentin R, Girard J, Postic C. (2005) Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 87:81-86
56. Sorkin A, Von Zastrow M (2002) Signal transduction and endocy-tosis: close encounters of many kinds. Nat Rev Mol Cell Biol 3:600-614
57. Pierce KL, Lefkowitz R.J. (2001) Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2:727-733
58. Pierce KL, Premont RT, Lefkowitz R.J. (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3:639-650
59. Winter EE, Ponting C.P. (2005) Mammalian BEX, WEX and GASP genes: coding and non-coding chimaerism sustained by gene conversion events. BMC Evol Biol 5:54
60. Vilar M, Murillo-Carretero M, Mira H., Magnusson K, Besset V, Ibanez C.F. (2006) Bex1, a novel interactor of the p75 neurotrophin receptor, links neurotrophin signaling to the cell cycle. EMBO J 25:1219-1230
61. Ding K, Su Y, Pang L., Lu Q, Wang Z, Zhang S., Zheng S, Mao J, Zhu Y (2009) Inhibition of apoptosis by downregulation of hBex1, a novel mechanism, contributes to the chemoresistance of Bcr/Abl+leukemic cells. Carcinogenesis 30:35-42
62. Khazaei MR, Halfter H, Karimzadeh F., Koo JH, Margolis FL, Young P. (2010) Bex1 is involved in the regeneration of axons after injury. J Neurochem 115:910-920
63. Carney DS, Davies BA, Horazdovsky B.F. (2006) Vps9 domain-containing proteins: activators of Rab5 GTPases from yeast to neurons. Trends Cell Biol 16:27-35
64. Galvis A, Giambini H, Villasana Z., Barbieri M.A. (2009) Functional determinants of ras interference 1 mutants required for their inhibitory activity on endocytosis. Exp Cell Res 315:820-835
65. Galvis A, Balmaceda V, Giambini H., Conde A, Villasana Z, Fornes M.W., Barbieri M.A. (2009) Inhibition of early endosome fusion by Rab5-binding defective Ras interference 1 mutants. Arch Biochem Biophys 482:83-95
66. Kong C, Su X, Chen P.I., Stahl P.D. (2007) Rin1 interacts with signal-transducing adaptor molecule (STAM) and mediates epidermal growth factor receptor trafficking and degradation. J Biol Chem 282:15294-15301
67. Bliss JM, Gray EE, Dhaka A, O'Dell TJ, Colicelli J. (2010) Fear learning and extinction are linked to neuronal plasticity through Rin1 signaling. J Neurosci Res 88:917-926
68. Dzudzor B, Huynh L, Thai M., Bliss JM, Nagaoka Y, Wang Y, Ch'ng TH, Jiang M, Martin KC, Colicelli J (2010) Regulated expression of the Ras effector Rin1 in forebrain neurons. Mol Cell Neurosci 43:108-116
69. Wang Y, Waldron RT, Dhaka A, Patel A., Riley MM, Rozengurt E, Colicelli J. (2002) The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-3 proteins. Mol Cell Biol 22:916-926
70. Dhaka A, Costa RM, Hu H, Irvin D.K., Patel A., Kornblum HI, Silva AJ, O'Dell TJ, Colicelli J. (2003) The RAS effector RIN1 modulates the formation of aversive memories. J Neurosci 23:748-757
71. Deininger K, Eder M, Kramer E.R., Zieglgansberger W., Dodt HU, Dornmair K, Colicelli J, Klein R. (2008) The Rab5 guanylate exchange factor Rin1 regulates endocytosis of the EphA4 receptor in mature excitatory neurons. Proc Natl Acad Sci USA 105:12539-12544
72. Manavalan M, Mishra M, Sze S.K., Heese K. (2013) Brain-site-specific proteome changes induced by neuronal p60TRP expression. Neurosignals. doi:10.1159/000343672
73. Woscholski R, Finan PM, Radley E, Totty N.F., Sterling AE, Hsuan JJ, Waterfield MD, Parker P.J. (1997) Synaptojanin is the major constitutively active phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase in rodent brain. J Biol Chem 272:9625-9628
74. Lee SY, Wenk MR, Kim Y, Nairn A.C., De Camilli P (2004) Regulation of synaptojanin 1 by cyclin-dependent kinase 5 at synapses. Proc Natl Acad Sci USA 101:546-551
75. Voronov SV, Frere SG, Giovedi S, Pollina E.A., Borel C., Zhang H, Schmidt C, Akeson E.C., Wenk MR, Cimasoni L, Arancio O, Davisson MT, Antonarakis SE, Gardiner K, De Camilli P, Di Paolo G (2008) Synaptojanin 1-linked phosphoinositide dysho-meostasis and cognitive deficits in mouse models of Down's syndrome. Proc Natl Acad Sci USA 105:9415-9420
76. Saito T, Guan F, Papolos D.F., Lau S., Klein M, Fann CS, Lachman H.M. (2001) Mutation analysis of SYNJ1: a possible candidate gene for chromosome 21q22-linked bipolar disorder. Mol Psychiatry 6:387-395
77. Vazquez-Higuera J.L., Mateo I, Sanchez-Juan P, Rodriguez-Rodriguez E, Pozueta A, Calero M., Dobato JL, Frank-Garcia A, Valdivieso F, Berciano J, Bullido MJ, Combarros O (2011) Genetic variation in the tau protein phosphatase-2A pathway is not associated with Alzheimer's disease risk. BMC Res Notes 4:327
78. Iqbal K, Wang X, Blanchard J., Liu F, Gong CX, Grundke-Iqbal I (2010) Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. Biochem Soc Trans 38:962-966
79. Iqbal K, Liu F, Gong C.X., Alonso Adel C, Grundke-Iqbal I (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118:53-69
80. Qian W, Shi J, Yin X., Iqbal K, Grundke-Iqbal I, Gong CX, Liu F. (2010) PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 19:1221-1229
81. Nagai Y, Ogasawara A, Heese K. (2004) Possible mechanisms of A beta(1-40)-or A beta(1-42)-induced cell death and their rescue factors. Nihon Yakurigaku Zasshi 124:135-143
82. He G, Luo W, Li P., Remmers C, Netzer WJ, Hendrick J, Bettayeb K., Flajolet M, Gorelick F, Wennogle LP, Greengard P (2010) Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467:95-98
83. Bellucci A, Navarria L, Zaltieri M., Missale C, Spano P. (2012) Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Res 1432:95-113
84. Schulz-Schaeffer WJ (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 120:131-143
85. Yasuda T, Mochizuki H. (2010) The regulatory role of alpha-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease. Apoptosis 15:1312-1321
86. Cheng F, Li X, Li Y., Wang C, Wang T, Liu G., Baskys A, Ueda K, Chan P, Yu S (2011) alpha-Synuclein promotes clathrin-mediated NMDA receptor endocytosis and attenuates NMDA-induced do-paminergic cell death. J Neurochem 119:815-825
87. Sherer TB, Betarbet R, Greenamyre J.T. (2001) Pathogenesis of Parkinson's disease. Curr Opin Investig Drugs 2:657-662
88. Huls S, Hogen T, Vassallo N., Danzer KM, Hengerer B, Giese A, Herms J. (2011) AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced alpha-synuclein oligomers. J Neurochem 117:868-878
89. Anwar S, Peters O, Millership S., Ninkina N, Doig N, Connor-Robson N, Threlfell S., Kooner G, Deacon RM, Bannerman DM, Bolam JP, Chandra SS, Cragg SJ, Wade-Martins R, Buchman VL (2011) Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci 31:7264-7274
90. Varkey J, Isas JM, Mizuno N, Jensen M.B., Bhatia VK, Jao CC, Petrlova J, Voss J.C., Stamou DG, Steven AC, Langen R (2010) Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J Biol Chem 285:32486-32493
91. Beyer K, Ispierto L, Latorre P., Tolosa E, Ariza A. (2011) Alpha-and beta-synuclein expression in Parkinson disease with and without dementia. J Neurol Sci 310:112-117
92. Beyer K, Munoz-Marmol AM, Sanz C., Marginet-Flinch R, Ferrer I, Ariza A. (2012) New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases. Neurogenetics 13:61-72
93. Shaltiel-Karyo R., Frenkel-Pinter M, Egoz-Matia N, Frydman-Marom A, Shalev D.E., Segal D., Gazit E. (2010) Inhibiting alpha-synuclein oligomerization by stable cell-penetrating beta-synuclein fragments recovers phenotype of Parkinson's disease model flies. PLoS One 5:e13863
94. Jabbari K, Bernardi G. (2004) Cytosine methylation and CpG, TpG (CpA) and TpA frequencies. Gene 333:143-149
95. Jacinto FV, Ballestar E, Ropero S., Esteller M. (2007) Discovery of epigenetically silenced genes by methylated DNA immunoprecip-itation in colon cancer cells. Cancer Res 67:11481-11486